AVIR

Atea Pharmaceuticals Inc

AVIR, USA

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

https://ateapharma.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
AVIR
stock
AVIR

Growth Report: What is Potbelly Corporations book value per share - Weekly Stock Summary & Expert Approved Trade Ideas baoquankhu1.vn

Read more →
AVIR
stock
AVIR

Moving Averages: Can Amcor plc stock outperform in a bear market - Analyst Upgrade & Free Technical Confirmation Trade Alerts baoquankhu1.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$7.6667

Analyst Picks

Strong Buy

1

Buy

0

Hold

1

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.87

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-13.32 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-12.26 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.09

Low 1

High 0.3

Investors

* Institutions hold a combined 78.35% of the total shares of Atea Pharmaceuticals Inc

1.

BlackRock Inc

(10.9234%)

since

2025/06/30

2.

BML Capital Management LLC

(9.5893%)

since

2025/06/30

3.

FMR Inc

(7.2076%)

since

2025/06/30

4.

TANG CAPITAL MANAGEMENT LLC

(6.161%)

since

2025/06/30

5.

Vanguard Group Inc

(6.1585%)

since

2025/06/30

6.

Fidelity Growth Compy Commingled Pl S

(4.868%)

since

2025/07/31

8.

Vanguard Total Stock Mkt Idx Inv

(2.9939%)

since

2025/07/31

9.

Geode Capital Management, LLC

(2.4265%)

since

2025/06/30

10.

iShares Russell 2000 ETF

(2.2604%)

since

2025/08/31

11.

State Street Corp

(2.2385%)

since

2025/06/30

12.

Dimensional Fund Advisors, Inc.

(1.7784%)

since

2025/06/30

13.

Renaissance Technologies Corp

(1.5551%)

since

2025/06/30

14.

Fidelity Growth Company Fund

(1.1822%)

since

2025/07/31

15.

Vanguard Institutional Extnd Mkt Idx Tr

(1.1163%)

since

2025/07/31

16.

Fidelity Small Cap Index

(0.9529%)

since

2025/06/30

17.

Two Sigma Advisers, LLC

(0.8832%)

since

2025/06/30

18.

Northern Trust Corp

(0.8512%)

since

2025/06/30

19.

Fidelity Growth Company K6

(0.8458%)

since

2025/07/31

20.

BlackRock Advantage Small Cap Core Instl

(0.8388%)

since

2025/07/31

21.

iShares Russell 2000 Value ETF

(0.8355%)

since

2025/08/31

22.

JPMorgan Chase & Co

(0.8224%)

since

2025/06/30

23.

Charles Schwab Investment Management Inc

(0.8005%)

since

2025/06/30

24.

Newtyn Management LLC

(0.7309%)

since

2025/06/30

25.

Morgan Stanley - Brokerage Accounts

(0.6858%)

since

2025/06/30

26.

CM Management, LLC

(0.6301%)

since

2025/06/30

27.

Peapod Lane Capital LLC

(0.5702%)

since

2025/06/30

28.

Almitas Capital LLC

(0.5612%)

since

2025/06/30

29.

iShares Biotechnology ETF

(0.5243%)

since

2025/08/31

30.

Fidelity Extended Market Index

(0.5107%)

since

2025/07/31

31.

Two Sigma Investments LLC

(0.462%)

since

2025/06/30

32.

Vanguard Russell 2000 ETF

(0.4591%)

since

2025/07/31

33.

Schwab US Small-Cap ETF™

(0.4542%)

since

2025/08/30

34.

DFA US Targeted Value I

(0.4512%)

since

2025/07/31

35.

Dimensional US Targeted Value ETF

(0.3846%)

since

2025/08/29

36.

State St Russell Sm Cap® Indx SL Cl I

(0.3772%)

since

2025/08/31

37.

Vanguard Strategic Equity Inv

(0.3508%)

since

2025/06/30

38.

SQUAD Aguja Opportunities I

(0.3024%)

since

2025/05/31

39.

Schwab Small Cap Index

(0.2432%)

since

2025/07/31

40.

NT R2000 Index Fund - NL

(0.2335%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-0.53

EPS Estimate

-0.42

EPS Difference

-0.11

Surprise Percent

-26.1905%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(3)
Net Net
Possible Net-Net(5)
Quality
Low Quality Business(2.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.